prescription cannabis made uk biotech firm gw pharmaceuticals set approved canada
used treat central nervous system alleviate symptoms multiple sclerosis ms
weeks ago shares gw pharma lost third value uk regulators said wanted evidence drugs benefits
canadian authorities said sativex considered approval
approximately 50000 people canada diagnosed ms 85000 people suffering condition uk
many patients already smoke cannabis relieve symptoms
gw pharmas sativex mouth spray could legally available ms sufferers canada within next months
first time cannabisbased approved anywhere world representing landmark gw pharma patients ms
final approval canada little formality analysts said company expects full approval sativex early 2005
delighted receive qualifying notice health canada look forward receiving regulatory approval sativex canada early part 2005 said gw pharma executive chairman dr geoffrey guy
uk government granted gw pharma licence grow cannabis plant medical research purposes
satifex consists cannabis extract containing tetrahydrocannabinol cannabidiol cocktail proved effective treating patients arthritis
thousands plants grown secret location somewhere english countryside
despite hopes regulatory approval last year series delays put back sativexs launch uk
latest news sent shares gw pharma 85p 81 1135p

